Results 91 to 100 of about 1,324,041 (317)

271 Evaluation of treatment for opioid use disorder across North Carolina: a study protocol

Journal of Clinical and Translational Science
OBJECTIVES/GOALS: Our objectives are to: 1) characterize opioid treatment providers in North Carolina according to payment methods accepted and ability to provide medications for opioid use disorder and 2) use geomapping technology to characterize ...
Rachel Lynn Graves, Janine Short, Erin W. Barnes, Jason Stopyra   +3 more
doaj   +1 more source

Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System.

NAM Perspectives, 2020
Even though evidence-based treatment for opioid use disorders (OUD) is effective, almost four in five Americans with OUD do not receive any form of treatment.
B. Madras, Jia Ahmad, Jenny Wen, J. Sharfstein   +3 more
semanticscholar   +1 more source

Validation of Two Diagnostic Assessments for Opioid and Stimulant Use Disorder for Use by Non‐Clinicians

Psychiatric Research and Clinical Practice, 2023
Objective The United States is in the fourth wave of the opioid epidemic marked by the increase in fentanyl and co‐occurring stimulant use related overdose deaths.
Angela Di Paola, David Farabee, Sandra A. Springer   +2 more
doaj   +1 more source

Trends in opioid prescribing in Scandinavian countries from 2010 to 2023: Insights from multi‐metric evaluation

British Journal of Clinical Pharmacology, EarlyView.
Aims Monitoring opioid prescribing across different healthcare systems is essential to understanding population‐level exposure and informing global health policies. This study examined opioid utilization in Scandinavian countries between 2010 and 2023 using multiple complementary metrics, addressing the limitations of single‐metric comparisons ...
Gabriela Rolová, Svetlana Skurtveit, Marte Handal, Geana Paula Kurita, Torgeir Gilje Lid, Ingvild Odsbu, Mikael Hoffmann   +6 more
wiley   +1 more source

Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder

Addiction Science & Clinical Practice
Background Medications for opioid use disorder (MOUD) are among the best tools available to combat the opioid epidemic. Yet, use of MOUD among people with opioid use disorder (OUD) remains low.
Nicholas C. Cardamone, Rebecca E. Stewart, Kyle M. Kampman, Steven C. Marcus   +3 more
doaj   +1 more source

Efficacy and safety of a selective partial agonist for nociception/orphanin‐FQ peptide (NOP) receptors in patients with insomnia disorder

British Journal of Clinical Pharmacology, EarlyView.
Aims Insomnia is a common sleep disorder, affecting up to 20% of the world population and adversely impacting productivity, health, and overall well‐being. Although pharmacologic options exist to treat insomnia, the health‐related quality of life for patients who are prescribed hypnotics is no higher than for those who are not, revealing a significant ...
Garth T. Whiteside, Ellie He, Manjunath S. Shet, Mingyan Zhou, Maha Ahmad, Stephen C. Harris   +5 more
wiley   +1 more source

Pregabalin dependence, withdrawal, suicidality and psychosis reports: A disproportionality analysis of the Australian adverse events database

British Journal of Clinical Pharmacology, EarlyView.
Aims Globally, Australia has the highest per capita consumption rate of pregabalin, commonly prescribed for neuropathic pain. Emerging evidence suggests pregabalin may be associated with the onset or recurrence of several potentially life‐threatening psychiatric events in some individuals.
Amy G. McNeilage, Ali Gholamrezaei, Bridin Murnion, Suzanne Nielsen, Claire E. Ashton‐James   +4 more
wiley   +1 more source

Prescription use of acetaminophen among pregnant women in Denmark from 2000 to 2023: A drug utilization study

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this study was to describe prescription use of acetaminophen, a widely used analgesic and antipyretic generally considered safe during pregnancy, among pregnant women from 2000 to 2023 in Denmark with special attention towards variations following the change in over‐the‐counter (OTC) availability in 2013.
Erika B. Gram, Mette Bliddal, Sophie Pflugfelder, Peter Bjødstrup Jensen, Per Damkier   +4 more
wiley   +1 more source

Psychoactive prescription drug use and misuse in patients on opioid agonist treatment

British Journal of Clinical Pharmacology, EarlyView.
Aims To identify the patterns and trends in prescription drug use and misuse in patients on opioid agonist treatment. Methods We used data from the OPPIDUM programme, which collects data from patients attending substance abuse treatment facilities. Data collected include use of psychoactive prescription drugs in the past week.
Thomas Soeiro, Clémence Lacroix, Élisabeth Jouve, Élisabeth Frauger, Maryse Lapeyre‐Mestre, Joëlle Micallef   +5 more
wiley   +1 more source

Emerging neuromodulation treatments for opioid and stimulant use disorders

Frontiers in Human Neuroscience
Over the past decade, deaths attributable to opioid and stimulant use have risen dramatically. While the U.S. Food and Drug Administration (FDA) has approved three medications for opioid use disorder, there is currently no FDA-approved treatment for ...
Susanna D. Howard, Liming Qiu, Nathan Hager, Anna Rose Childress, Casey H. Halpern, Katherine W. Scangos, Katherine W. Scangos   +6 more
doaj   +1 more source